LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided an update on recent progress with its clinical programs and reported financial results for the quarter ended September 30, 2011.
“Based on encouraging results seen with ganetespib in lung cancer and other tumor types, we have established an exciting and diverse clinical development plan that could generate six to eight significant data readouts in 2012 in distinct patient populations, each of which offers a potential path to registration,” said Safi Bahcall, Ph.D., President and CEO.
“Based on encouraging results seen with ganetespib in lung cancer and other tumor types, we have established an exciting and diverse clinical development plan that could generate six to eight significant data readouts in 2012 in distinct patient populations, each of which offers a potential path to registration,” said Safi Bahcall, Ph.D., President and CEO.
